As for the JAK2-associated CH, Wolach et al. [70] demonstrated that treatment of thrombosis-prone Jak2V617F mice with ruxolitinib, a clinically available JAK2 inhibitor, reduced the propensity for thromb formation. The gene discussed is JAK2; the disease is cyclic hematopoiesis.